Skip to content

HR 9661 · 119th Congress

To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.

Introduced Jul 14, 2026Last action Jul 14, 2026Congress.gov →

Latest action

Referred to the House Committee on Energy and Commerce.

Sponsor

Nicholas A. LangworthyRepublican · NY-23Profile →

Cosponsors (1)

1 D